Objectives Compare the effect of apixaban and warfarin on coagulation and primary
haemostasis biomarkers in atrial fibrillation (AF). Methods The biomarker substudy from the …

Summary Background The Apixaban for Reduction in Stroke and Other Thromboembolic
Events in Atrial Fibrillation (ARISTOTLE) trial showed that apixaban is better than warfarin at …

Abstract Introduction The direct factor-Xa inhibitor apixaban is approved eg for the
prevention of stroke in patients with atrial fibrillation (AF). Although routine monitoring of …

In some clinical situations, measurements of anticoagulant effect of apixaban may be
needed. We investigated the inter-and intra-individual apixaban variability in patients with …

Aim To assess clinical outcomes, efficacy, and safety according to sex during
anticoagulation with apixaban compared with warfarin in patients with atrial fibrillation …

Background Patients with atrial fibrillation who are vitamin K antagonist (VKA)-naive may
have a higher risk of thrombosis and/or bleeding than VKA-experienced patients. Methods …

Aims It is uncertain whether the benefit from apixaban varies by type and duration of atrial
fibrillation (AF). Methods and results A total of 18 201 patients with AF [2786 (15.3%) with …

Background Vitamin K antagonists have been shown to prevent stroke in patients with atrial
fibrillation. However, many patients are not suitable candidates for or are unwilling to receive …

Background: This study evaluated whether measuring prothrombin time (PT) using particular
reagents of interest predicted apixaban-associated anticoagulant activity in Japanese …

Background—Apixaban is approved for the prevention of stroke and systemic embolism in
patients with nonvalvular atrial fibrillation. However, the Apixaban for Reduction in Stroke …